17-valent recombinant human papillomavirus vaccine (Hansenula polymorpha, China National Biotec Group)

十七价重组人乳头瘤病毒疫苗（汉逊酵母，重庆博唯佰泰生物）

Report date: 2022/08/05 10:18:31

Base Information

Drug Name17-valent recombinant human papillomavirus vaccine (Hansenula polymorpha, China National Biotec Group)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesChongqing Bovax Biopharmaceutical Co LtdShanghai Bovax Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Bovax Biopharmaceutical Co LtdShanghai Bovax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A